Bacteriocins and lipopeptides potently inhibit 40 *Listeria monocytogenes* isolates, overcoming antibiotic resistance.
Background
Listeria monocytogenes is a significant foodborne pathogen, posing serious threats to global food safety and public health. Current treatment strategies often rely on conventional antibiotics, but the increasing prevalence of antibiotic resistance is a growing concern, limiting therapeutic options and driving the need for novel antimicrobial agents. This study explores antimicrobial peptides (AMPs) and bacteriocins as promising alternatives, leveraging their diverse structures and mechanisms of action to combat resistant strains and improve food preservation strategies. The focus is on finding potent inhibitors that can overcome the pathogen's defense mechanisms.
Study Design
Researchers investigated the inhibitory activity of six diverse antimicrobial peptides against 40 Listeria monocytogenes isolates sourced from clinical, environmental, and food samples. The selected peptides included the bacteriocins bactofencin A (M14L, M18L), nisin Z, pediocin PA-1 (M31L), and plantaricin S, alongside the lipopeptides brevibacillin and its synthetic analog brevibacillin Thr1. Antibiotic susceptibility assays were performed, and virulome analysis identified the prfA-virulence gene cluster in selected strains. Primary endpoints were minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC). Comparative genomic and structural impact analysis were conducted to understand susceptibility variability.
Results
All six tested peptides demonstrated significant inhibitory activity across all 40 Listeria monocytogenes isolates. The minimal inhibitory and bactericidal concentrations ranged broadly between 0.54 µM and 18.20 µM, highlighting their potent antimicrobial effects. Notably, this antimicrobial activity was generally not associated with the isolates' existing antibiotic resistance profiles or the presence/absence of specific virulence genes like the prfA cluster. > High resistance to clindamycin was observed among the isolates, with four isolates resistant to at least one or two antibiotics, underscoring the urgent need for alternative treatments. Further comparative genomic and structural impact analyses revealed specific polymorphisms in genes linked to stress response, efflux pumps, membrane integrity, and protein biosynthesis. These genetic variations are hypothesized to contribute to the observed variability in susceptibility among different Listeria isolates, providing insights into potential resistance mechanisms against AMPs.
Key Findings
- Six antimicrobial peptides inhibited all 40 Listeria monocytogenes isolates.
MICandMBCvalues ranged from 0.54 µM to 18.20 µM.- Peptide activity was independent of antibiotic resistance or virulence gene presence.
- Genomic polymorphisms in
stress response,efflux pumps,membrane, andprotein biosynthesisgenes explain susceptibility variability. - High resistance to clindamycin was observed in Listeria isolates.
Why It Matters
Antimicrobial peptides represent a powerful alternative to conventional antibiotics for controlling Listeria monocytogenes, particularly in the face of rising antibiotic resistance. This research validates the broad-spectrum efficacy of several structurally diverse bacteriocins and lipopeptides against a wide range of Listeria isolates, including those resistant to common antibiotics like clindamycin. The findings suggest these peptides could be integrated into novel food preservation strategies or developed into therapeutic agents for listeriosis, potentially offering new protocols for mitigating foodborne illness. Understanding the genetic basis of susceptibility variability also informs future peptide design, allowing for optimized agents that circumvent bacterial defense mechanisms.